Trial Profile

Assessment of Adherence, Effectiveness and Convenience of Rebif Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon beta-1a (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms SMART
Sponsors Merck KGaA

Most Recent Events

23 Jun 2015 Results (follow-up of German cohort) presented at the 1st Congress of the European Academy of Neurology.
03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
19 Sep 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com